ACOR - Acorda Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Ardsley,
United States
Type: Equity
ACOR price evolution
ACOR
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $30.61 | $33.58 | $26.35 | $37.75 |
| Short term investments | ||||
| Net receivables | $17.3 | $11.98 | $13.39 | $9.19 |
| Inventory | $16.16 | $17.94 | $14.8 | $13.46 |
| Total current assets | $74.79 | $73.73 | $64.91 | $68.09 |
| Long term investments | ||||
| Property, plant & equipment | $6.3 | $6.71 | $6.93 | $7.41 |
| Goodwill & intangible assets | $22.99 | $282.01 | $289.7 | $297.39 |
| Total noncurrent assets | $33.73 | $292.62 | $299.78 | $306.81 |
| Total investments | ||||
| Total assets | $108.53 | $366.34 | $364.7 | $374.91 |
| Current liabilities | ||||
| Accounts payable | $13.37 | $12.33 | $3.17 | $2.85 |
| Deferred revenue | $0.23 | $0.47 | $0.55 | |
| Short long term debt | $187.73 | $1.58 | $1.57 | $1.56 |
| Total current liabilities | $227.77 | $46.29 | $30.39 | $34.74 |
| Long term debt | $3.17 | $184.51 | $179.93 | $175.55 |
| Total noncurrent liabilities | $38.71 | $261.09 | $266.44 | $263.21 |
| Total debt | $190.9 | $186.09 | $181.5 | $177.11 |
| Total liabilities | $266.48 | $307.39 | $296.83 | $297.95 |
| Shareholders' equity | ||||
| Retained earnings | -$1189.13 | -$971.37 | -$962.48 | -$953.1 |
| Other shareholder equity | $1.43 | $0.72 | $0.88 | $0.72 |
| Total shareholder equity | -$157.96 | $58.96 | $67.87 | $76.96 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $30.61 | $44.67 | $65.22 | $102.89 |
| Short term investments | ||||
| Net receivables | $17.3 | $13.87 | $17 | $20.19 |
| Inventory | $16.16 | $12.75 | $18.55 | $28.68 |
| Total current assets | $74.79 | $82.11 | $102.16 | $221.34 |
| Long term investments | ||||
| Property, plant & equipment | $6.3 | $7.89 | $11.13 | $25.74 |
| Goodwill & intangible assets | $22.99 | $305.09 | $335.98 | $366.98 |
| Total noncurrent assets | $33.73 | $313.48 | $353.31 | $411.35 |
| Total investments | ||||
| Total assets | $108.53 | $395.6 | $455.47 | $632.68 |
| Current liabilities | ||||
| Accounts payable | $13.37 | $9.81 | $10.85 | $12.15 |
| Deferred revenue | $0.23 | $0.38 | ||
| Short long term debt | $187.73 | $1.54 | $8.19 | $76.58 |
| Total current liabilities | $227.77 | $37.95 | $54.02 | $137.25 |
| Long term debt | $3.17 | $167.03 | $182.76 | $183.37 |
| Total noncurrent liabilities | $38.71 | $264.02 | $250.31 | $257.47 |
| Total debt | $190.9 | $172.92 | $190.94 | $259.95 |
| Total liabilities | $266.48 | $301.97 | $304.33 | $394.73 |
| Shareholders' equity | ||||
| Retained earnings | -$1189.13 | -$936.27 | -$870.36 | -$766.4 |
| Other shareholder equity | $1.43 | $0.63 | -$1.02 | -$2.8 |
| Total shareholder equity | -$157.96 | $93.62 | $151.14 | $237.96 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $37.98 | $27.71 | $29.68 | $22.26 |
| Cost of revenue | $5.6 | $3.39 | $3.06 | $3.23 |
| Gross Profit | $32.39 | $24.33 | $26.61 | $19.02 |
| Operating activities | ||||
| Research & development | $1.01 | $1.21 | $1.55 | $1.39 |
| Selling, general & administrative | $22.21 | $23.15 | $21.82 | $22.51 |
| Total operating expenses | $282.23 | $32.05 | $31.07 | $31.59 |
| Operating income | -$249.84 | -$7.72 | -$4.46 | -$12.57 |
| Income from continuing operations | ||||
| EBIT | -$247.66 | -$1.96 | -$3.57 | -$11.29 |
| Income tax expense | -$38.11 | -$1.05 | -$1.97 | -$2.04 |
| Interest expense | $8.21 | $7.98 | $7.77 | $7.57 |
| Net income | ||||
| Net income | -$217.76 | -$8.89 | -$9.38 | -$16.82 |
| Income (for common shares) | -$217.76 | -$8.89 | -$9.38 | -$16.82 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $117.63 | $118.57 | $129.07 | $152.97 |
| Cost of revenue | $15.28 | $30.33 | $40.79 | $33.51 |
| Gross Profit | $102.35 | $88.23 | $88.28 | $119.45 |
| Operating activities | ||||
| Research & development | $5.15 | $5.8 | $10.42 | $23.01 |
| Selling, general & administrative | $89.7 | $106.26 | $124.4 | $152.58 |
| Total operating expenses | $376.94 | $130.27 | $165.58 | $268.38 |
| Operating income | -$274.59 | -$42.04 | -$77.3 | -$148.92 |
| Income from continuing operations | ||||
| EBIT | -$264.49 | -$5.05 | -$79.04 | -$77.09 |
| Income tax expense | -$43.17 | $30.67 | -$5.12 | -$8.07 |
| Interest expense | $31.53 | $30.2 | $30.04 | $30.57 |
| Net income | ||||
| Net income | -$252.85 | -$65.92 | -$103.95 | -$99.59 |
| Income (for common shares) | -$252.85 | -$65.92 | -$103.95 | -$99.59 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$217.76 | -$8.89 | -$9.38 | -$16.82 |
| Operating activities | ||||
| Depreciation | $7.91 | $7.9 | $7.88 | $7.91 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.14 | $0.14 | $0.13 | $0.07 |
| Total cash flows from operations | -$3.02 | $7.61 | -$11.56 | -$7.02 |
| Investing activities | ||||
| Capital expenditures | -$0.04 | -$0.22 | ||
| Investments | ||||
| Total cash flows from investing | -$0.04 | -$0.22 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | ||||
| Effect of exchange rate | $0.09 | -$0.16 | $0.15 | $0.1 |
| Change in cash and equivalents | -$2.97 | $7.23 | -$11.4 | -$6.92 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$252.85 | -$65.92 | -$103.95 | -$99.59 |
| Operating activities | ||||
| Depreciation | $31.6 | $32.81 | $33.95 | $41.3 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.48 | $1.49 | $3 | $8.1 |
| Total cash flows from operations | -$13.98 | -$20.92 | -$41.35 | -$61.01 |
| Investing activities | ||||
| Capital expenditures | -$0.26 | -$0.14 | -$0.17 | -$4.39 |
| Investments | $73.97 | $63.75 | ||
| Total cash flows from investing | -$0.26 | -$0.14 | $73.78 | $59.36 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$69.66 | -$1.67 | ||
| Total cash flows from financing | -$69.66 | -$1.67 | ||
| Effect of exchange rate | $0.19 | $0.51 | -$0.45 | $1.02 |
| Change in cash and equivalents | -$14.06 | -$20.55 | -$37.67 | -$2.3 |
News
Fundamentals
| Market cap | $320.46K |
|---|---|
| Enterprise value | $160.60M |
| Shares outstanding | 1.24M |
| Revenue | $117.63M |
|---|---|
| EBITDA | -$232.89M |
| EBIT | -$264.49M |
| Net Income | -$252.85M |
| Revenue Q/Q | 20.70% |
| Revenue Y/Y | N/A |
| P/E ratio | -0.00 |
|---|---|
| EV/Sales | 1.37 |
| EV/EBITDA | -0.69 |
| EV/EBIT | -0.61 |
| P/S ratio | 0.00 |
| P/B ratio | -0.00 |
| Book/Share | -128.32 |
| Cash/Share | 24.65 |
| EPS | -$203.57 |
|---|---|
| ROA | -83.28% |
| ROE | -2.21K% |
| Debt/Equity | -1.69 |
|---|---|
| Net debt/EBITDA | -1.01 |
| Current ratio | 0.33 |
| Quick ratio | 0.26 |